Publications by authors named "F Gerhardt"
The PEGASUS study is the first multicentric and prospective assessment of the safety of air travel flying in pulmonary hypertension (PH) (NCT03051763). Data of air travel from 60 patients with PH was available. No severe adverse events occurred.
View Article and Find Full Text PDFArticle Synopsis
- Differentiating between recurrent cerebral metastasis (CM) and brain radiation necrosis (BRN) is crucial for treatment decisions, but current imaging techniques struggle to make accurate distinctions.
- In a study analyzing 32 cases of cerebral metastases, conventional MRI accurately identified CM in only 75% of cases, while MR perfusion scans revealed higher blood volume in metastasis but couldn’t definitively differentiate the two conditions.
- The research highlights the need for histopathological examination for accurate diagnosis and suggests further studies to enhance non-invasive imaging techniques for better management of patients experiencing these complications.
Background: Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute vasoresponders, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate the implications of acute vasoreactivity response for long-term response to CCBs and other outcomes.
View Article and Find Full Text PDFAims: In pulmonary arterial hypertension (PAH), upfront combination therapy with ERA and PDE5i is associated with a reduction in morbidity and mortality events and improves standard haemodynamics, but data remain limited. Aims of this study were (i) to capture detailed haemodynamic effects of rapid sequential dual combination therapy in patients with newly diagnosed PAH; (ii) to monitor the impact of treatment initiation on clinical variables and patients' risk status, and (iii) to compare the treatment effect in patients with 'classical PAH' and 'PAH with co-morbidities'.
Methods: Fifty patients (median age 57 [42-71] years, 66% female) with newly diagnosed PAH (76% idiopathic) were treated with a PD5i/sGC-S or ERA, followed by addition of the respective other drug class within 4 weeks.